SIGA Technologies, Inc. (SIGA)
| Market Cap | 587.22M |
| Revenue (ttm) | 139.92M |
| Net Income (ttm) | 68.07M |
| Shares Out | 71.09M |
| EPS (ttm) | 0.95 |
| PE Ratio | 8.96 |
| Forward PE | 7.47 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 344,508 |
| Open | 8.40 |
| Previous Close | 8.51 |
| Day's Range | 8.18 - 8.53 |
| 52-Week Range | 4.22 - 10.00 |
| Beta | 0.97 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 2, 2024 |
About SIGA
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York. [Read more]
Full Company ProfileFinancial Performance
In 2023, SIGA's revenue was $139.92 million, an increase of 26.31% compared to the previous year's $110.78 million. Earnings were $68.07 million, an increase of 100.76%.
Financial StatementsNews
SIGA Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX®
NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on health security and infectious disease, announced today that i...
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023
• Increased Product Sales to $131 Million in 2023 • Grew Pre-tax Operating Income to $84 Million in 2023 • Declared Today a Special Cash Dividend of $0.60 per Share • Corporate Update Conference Call ...
SIGA Declares Special Cash Dividend of $0.60 Per Share
NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special ca...
SIGA Technologies to Host Business Update Call on March 12th, 2024 Following Release of Fourth Quarter and Full Year 2023 Financial Results
NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conferenc...
SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer
NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Diem Ng...
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2023
- In Third Quarter, SIGA Received U.S. Government Orders for Approximately $113 Million of Oral TPOXX and $25 Million of IV TPOXX® -
SIGA Technologies to Host Business Update Call on November 7th, 2023 Following Release of Third Quarter 2023 Financial Results
NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference...
SIGA Announces Creation of Joint Procurement Mechanism by European Commission with Anticipated Initial Orders of Approximately $18 Million for Oral TPOXX® (Tecovirimat) by Participating Countries
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced the creation...
SIGA Technologies Names Dr. Jay K. Varma as EVP and Chief Medical Officer
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Ja...
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2023
- In July, SIGA Received U.S. Government Orders for Approximately $113 Million of Oral TPOXX and $25 Million of IV TPOXX® -
SIGA Announces U.S. Government Procurement Orders of Approximately $138 Million for Oral and IV TPOXX®
Exercise of Procurement Options of Approximately $113 Million for Oral TPOXX and Approximately $25 Million for IV TPOXX under Current Contract reflects continuing global action to enhance smallpox pre...
SIGA Technologies to Host Business Update Call on Tuesday, August 8th, 2023 Following Release of Second Quarter 2023 Financial Results
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference...
SIGA CEO Phil Gomez, PhD, to Present on Smallpox and Orthopox Preparedness at NATO Chemical, Biological, Radiological & Nuclear Medical Symposium
Inaugural meeting on June 28-30, 2023, to include updates from leading experts on strategies to plan for and address broad range of potential global health risks including biological and viral disease...
SIGA Reports Financial Results for Three Months Ended March 31, 2023
NEW YORK, May 04, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 3...
SIGA Declares Special Cash Dividend of $0.45 Per Share
NEW YORK, May 04, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that the Board of Directors declared a special cash...
SIGA Technologies to Host Business Update Call on May 4th, 2023 Following Release of First Quarter 2023 Financial Results
NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conferenc...
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2022
- Approximately $71 Million of International Product Sales in 2022 -
SIGA Technologies to Host Business Update Call on March 2nd, 2023 Following Release of Fourth Quarter and Full Year 2022 Financial Results
NEW YORK, Feb. 23, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference...
SIGA Technologies Announces Planned Retirement of CEO Phil Gomez in 2023
SIGA Board of Directors has initiated search for new CEO; Dr. Gomez expected to remain in position as CEO until the search is completed to support the transition to a new CEO in 2023 SIGA Board of Dir...
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2022
- Approximately $61 Million of International Sales in the Third Quarter –
SIGA Technologies to Host Business Update Call on November 3rd, 2022 Following Release of Third Quarter 2022 Financial Results
NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference...
SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox
NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today provided an update on ...
SIGA Technologies Announces New Contract Awarded by U.S. Department of Defense for the Procurement of up to $10.7 Million of Oral TPOXX®
- In 2022, the U.S. Department of Defense has Awarded Procurement Contracts for the Purchase of up to $18.1 Million of Oral TPOXX – - In 2022, the U.S. Department of Defense has Awarded Procurement Co...
SIGA Announces Approximately $16 Million of International Procurement Orders Received in August and Early September for Oral TPOXX® (Tecovirimat)
- Order for Approximately $10 Million Funded by the European Commission –
SIGA Announces BARDA Exercise of Procurement Options Valued at Approximately $26 Million for IV TPOXX®
- IV TPOXX is an Important Option for Those Unable to Swallow –